Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
Levodopa-induced onset and end-of-dose dyskinesia are rare but disabling disorders. Although they can be attenuated by increasing and dividing the daily dose of levodopa, this does not constitute a therapeutic approach. In this pilot study, etybenzatropine, an anticholinergic drug, and diazepam, a selective benzodiazepine, were administered in addition to a single dose of levodopa in nine patients with Parkinson's disease. Both drugs tended to decrease the severity and the duration of onset and end-of-dose dyskinesia and to increase the duration of action of levodopa on parkinsonian symptoms.
Pourcher
E
E
Clinique de Neurologie et Neuropsychologie, Paris, France.
Bonnet
A M
AM
Kefalos
J
J
Dubois
B
B
Agid
Y
Y
D003975:Diazepam / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects; D014326:Tropanes / Q000627:therapeutic use*
D014326:Tropanes; D007980:Levodopa; C027641:ethybenztropine; D003975:Diazepam